A new trading day began on Friday, with Adma Biologics Inc (NASDAQ: ADMA) stock price down -5.74% from the previous day of trading, before settling in for the closing price of $20.20. ADMA’s price has ranged from $3.60 to $23.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 73.26%. Meanwhile, its annual earnings per share averaged 494.23%. With a float of $228.39 million, this company’s outstanding shares have now reached $236.39 million.
The extent of productivity of a business whose workforce counts for 624 workers is very important to gauge. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.38%, while institutional ownership is 89.66%. The most recent insider transaction that took place on Sep 09 ’24, was worth 166,189. In this transaction Director of this company sold 9,000 shares at a rate of $18.47, taking the stock ownership to the 153,941 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Director proposed sale 9,000 for $16.26, making the entire transaction worth $146,340.
Adma Biologics Inc (ADMA) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.04 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 494.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Here are Adma Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.08. Likewise, its price to free cash flow for the trailing twelve months is 53.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
The latest stats from [Adma Biologics Inc, ADMA] show that its last 5-days average volume of 3.66 million was inferior to 3.67 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 33.74%. Additionally, its Average True Range was 1.17.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 65.75%, which indicates a significant increase from 39.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.40% in the past 14 days, which was higher than the 77.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.54, while its 200-day Moving Average is $11.86. Now, the first resistance to watch is $19.91. This is followed by the second major resistance level at $20.79. The third major resistance level sits at $21.23. If the price goes on to break the first support level at $18.59, it is likely to go to the next support level at $18.15. The third support level lies at $17.27 if the price breaches the second support level.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
With a market capitalization of 4.24 billion, the company has a total of 236,390K Shares Outstanding. Currently, annual sales are 258,220 K while annual income is -28,240 K. The company’s previous quarter sales were 119,840 K while its latest quarter income was 35,910 K.
